Skip to main content
Clinical Trials/NCT05952050
NCT05952050
Recruiting
Not Applicable

Effect of Different Administration Routes of Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing General Anesthesia

Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.1 site in 1 country120 target enrollmentAugust 1, 2023

Overview

Phase
Not Applicable
Intervention
Dexmedetomidine
Conditions
Dexmedetomidine
Sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Enrollment
120
Locations
1
Primary Endpoint
The frequency of delirium during the first 3 postoperative days
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (POD) in elderly patients. Nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. The current study aimed to compare the effect of different administration routes of dexmedetomidine on POD in elderly patients.

Registry
clinicaltrials.gov
Start Date
August 1, 2023
End Date
September 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Older than 65 years; General anesthesia for more than two hours;

Exclusion Criteria

  • Not provided

Arms & Interventions

Intranasal dexmedetomidine

Intervention: Dexmedetomidine

Intravenous dexmedetomidine

Intervention: Dexmedetomidine

Outcomes

Primary Outcomes

The frequency of delirium during the first 3 postoperative days

Time Frame: 3 days

Secondary Outcomes

  • The incidence of sleep quality(3 days)
  • The incidence of postoperative sore throat(3 days)

Study Sites (1)

Loading locations...

Similar Trials